SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges certain of RxSight’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the RXSight class action lawsuit, please provide your ...

LOS ANGELES, July 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its Q2 2025 financial results on July 9, 2025. The Company revealed ...

公司调查 - 股东权益律师事务所Robbins LLP正在调查RxSight公司（NASDAQ: RXST）是否存在高管及董事违反证券法或对股东未尽受托责任的行为 [1] - RxSight是一家商业阶段的医疗技术公司，专注于研发、生产和销售用于白内障手术的光可调节人工晶体（LAL），业务主要在美国市场 [1] 股东行动 - 若投资者持有RxSight股票并遭受损失，可联系该律所了解权利主张信息 [2] - 律所采用风险代理收费模式，股东无需预付费用 [3] - Robbins LLP自2002年起专注于股东诉讼，累计为股东追回超过10亿美元赔偿 [3] 附加服务 - 投资者可通过Stock Watch订阅服务，免费获取针对RxSight的集体诉讼和解或高管不当行为警报 [4]